VOY-101 in Advanced Non-Neovascular Age-Related Macular Degeneration
Age-Related Macular DegenerationThe Phase 1 safety study of VOY-101 comprises a two dose Cohort escalation, followed by a Phase 2a.
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular...
Neovascular Age-related Macular DegenerationNeovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of blindness in patients over 65 years of age. The abnormal angiogenic process in nAMD is stimulated and modulated by vascular endothelial growth factor (VEGF). Treatment of nAMD requires frequent intravitreal (IVT) injections of VEGF inhibitors (anti-VEGF) administered every 4-16 weeks. ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product being developed for the treatment of nAMD and offers the potential for sustained intraocular expression of aflibercept following a single IVT injection. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen...
Geographic AtrophyThis study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated.
This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection...
Wet Age-related Macular DegenerationThe purpose of this study is to compare the efficacy and safety of SCT510A versus Lucentis in the treatment of wet age-related macular degeneration.
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Eye Diseases...
Eye DiseasesRetinitis Pigmentosa5 moreThis trial will study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Eye diseases
Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration...
Age-Related Macular DegenerationKH631 is a adeno-associated virus (AAV) vector-based gene therapy for subretinal injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain vision.
QA108 Phase II Study in Subjects With Intermediate Age-Related Macular Degeneration
Intermediate Age-Related Macular DegenerationThis is a phase 2, randomized, double-masked, placebo-controlled, multicenter study. To evaluate the efficacy and safety of QA108 granules in the treatment of intermediate age-related macular degeneration.
Atrophic Age-related Macular Degeneration (AMD) Treated With Intravitreal Injections of Umbilical...
Dry Age-related Macular DegenerationThe objective of the study will be to evaluate the efficacy of intravitreal injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) in order to reduce or stabilize the atrophic progression in dry Age-related Macular Degeneration (AMD)
Efficacy and Safety of RC28-E Versus Aflibercept
Wet Age-related Macular DegenerationThis is a randomized, double-masked, multicenter study comparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) versus aflibercept in patients with wet age-related macular degeneration.
Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease
Stargardt DiseaseThis is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease. This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 42 subjects.